Cocrystal Pharma (NASDAQ:COCP) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Cocrystal Pharma (NASDAQ:COCP) issued its quarterly earnings data on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01, FiscalAI reports.

Cocrystal Pharma Price Performance

COCP stock opened at $1.02 on Tuesday. The company’s 50 day simple moving average is $1.02 and its 200-day simple moving average is $1.07. Cocrystal Pharma has a 12 month low of $0.86 and a 12 month high of $2.67. The firm has a market capitalization of $14.06 million, a PE ratio of -1.08 and a beta of 1.18.

Insider Activity

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of Cocrystal Pharma stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $47,500.00. Following the purchase, the director owned 1,888,551 shares in the company, valued at $1,794,123.45. This represents a 2.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 28.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent SEC filing. 6.72% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.